Ascendis Pharma Files 6-K Report
Ticker: ASND · Form: 6-K · Filed: Nov 26, 2025 · CIK: 1612042
Sentiment: neutral
Topics: sec-filing, 6-k, disclosure
Related Tickers: ASND
TL;DR
Ascendis Pharma (ASND) filed a 6-K, standard disclosure for foreign issuers.
AI Summary
Ascendis Pharma A/S filed a Form 6-K on November 26, 2025, for the month of November 2025. The company, incorporated in G7 with its principal executive offices in Hellerup, Denmark, is a pharmaceutical preparations company. This filing is incorporated by reference into their Form S-8 registration statements.
Why It Matters
This filing provides routine updates for Ascendis Pharma A/S, a foreign private issuer, to the SEC, ensuring transparency for investors regarding its corporate activities.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not appear to contain material new information.
Key Players & Entities
- Ascendis Pharma A/S (company) — Registrant
- 20251126 (date) — Filing Date
- 20251125 (date) — Period of Report
- Tuborg Boulevard 12 DK-2900 Hellerup Denmark (location) — Principal Executive Offices
- Form S-8 (Registration Numbers 333-203040 (document) — Incorporated by Reference
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer pursuant to Section 13a-16 or 15d-16 under the Securities Exchange Act of 1934, filed for the month of November 2025.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on November 26, 2025.
Where are Ascendis Pharma A/S's principal executive offices located?
The principal executive offices of Ascendis Pharma A/S are located at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.
What other SEC filings are referenced in this report?
This report on Form 6-K is incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040).
What is the SIC code for Ascendis Pharma A/S?
The Standard Industrial Classification (SIC) code for Ascendis Pharma A/S is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 710 words · 3 min read · ~2 pages · Grade level 20 · Accepted 2025-11-25 21:47:50
Filing Documents
- d24094d6k.htm (6-K) — 14KB
- 0001193125-25-297891.txt ( ) — 15KB
Forward-Looking Statements
Forward-Looking Statements This report contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this report regarding Ascendis' future operations, plans and objectives of management are forward-looking statements, including the statement relating to the PDUFA target action date for the NDA for TransCon CNP for children with achondroplasia. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis' products and product candidates; unforeseen safety or efficacy results in Ascendis' development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis' development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis' business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis' ability to obtain additional funding, if needed, to support its business activities; and the impact of international economic, political, legal, compliance, social and business factors, including tariffs and trade policies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ascendis Pharma A/S Date: November 25, 2025 By: /s/ Michael Wolff Jensen Michael Wolff Jensen Executive Vice President, Chief Legal Officer